The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?
Yu LH, Li N, Shi J, Guo WX, Wu MC, Cheng SQ. Ann Surg Oncol. 2013 Oct 12. [Epub ahead of print]
Author information
Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Abstract
The Hepatitis B virus (HBV) is an important etiological factor for hepatocarcinogenesis, because HBV DNA load and HBV reactivation are major risks that influence the long-term survival of hepatocellular carcinoma (HCC) patients who underwent hepatectomy and, thus, may cause postoperative liver function deterioration, tumor recurrence, and reduce patient's overall survival. However, anti-HBV therapy can suppress HBV replication, improve the remnant liver function, render patients better able to tolerate HCC treatments, and may even improve their prognosis. In this paper, an anti-HBV therapy that benefits the prognosis of HBV-related HCC following hepatectomy is reviewed.